Zimmer Biomet (ZBH) Q1 2026 Earnings Transcript

Zimmer Biomet reported Q1 net sales of $2.087 billion, up 9.3% reported and 2.9% organic constant currency, with adjusted EPS of $2.09 (+15%) and operating cash flow of $359 million. Management raised full-year adjusted EPS guidance to $8.40-$8.55 from $8.30-$8.45 and lifted free cash flow growth guidance to 9%-11%, while keeping sales guidance unchanged at 2.5%-4.5%. The quarter also featured 73% gross margin helped by a $0.20 tariff benefit, $250 million of share repurchases, accelerating Paragon 28 growth, and an interim CFO appointment amid a leadership transition.

Analysis

The important signal is not the quarter itself; it is that management is now monetizing the commercial reset faster than expected without yet needing to loosen the top-line framing. The sales-force conversion is creating a classic second-order effect: lower rep fragmentation should improve case coverage density and account control, which matters more in orthopedic recon than headline rep count. That dynamic can compound over the next 2-4 quarters because it hits procedure conversion, not just bookings, and it also explains why productivity can improve before reported revenue fully inflects.

The market is likely underestimating how much of the margin bridge is structural versus transitory. Tariff-driven gross margin upside is one-time, but the mix shift toward technology, dedicated reps, and better territory ownership can partially offset that fade if the company holds pricing erosion near current levels. The key bear case is that Q2 and Q3 become the true test: if the transition produces even modest account leakage or slower share recovery in knees, the stock may de-rate because investors are currently paying for a clean execution story into 2027.

The competitive implication is that smaller orthopedic peers and regional distributors are likely to lose share first, not the large diversified medtechs. The more interesting winner may be the company’s own ecosystem: robotics, navigation, and smart implant attach rates can rise as dedicated reps push bundles, raising switching costs and making pricing stickier. Conversely, if the new commercial model is less productive than advertised, the high-cost technology stack becomes a capital intensity problem rather than a growth lever.

Contrarian view: the consensus may be too focused on whether guidance was raised enough and not enough on the fact that management is effectively resetting the earnings quality profile. EPS upside from buybacks, tax, and tariffs is less durable than the underlying conversion of channel mix and technology penetration. That makes the next two prints more important than this one: if they confirm mid-single-digit international recovery and U.S. knee stabilization, the market will likely have to re-rate ZBH on a longer-duration margin story rather than a one-quarter beat.

Key Decisions for Investors

• Long ZBH on a 3-6 month horizon; risk/reward is favorable if the sales-force transition keeps improving productivity and the stock starts discounting 2027 margin durability rather than one-quarter tariff noise.
• Use a bull call spread in ZBH (6-9 month tenor) to express upside from a cleaner execution narrative while limiting downside if Q2 margin deceleration is sharper than expected.
• Pair trade: long ZBH / short a more execution-sensitive orthopedic peer or distributor-heavy medtech basket; thesis is that ZBH’s dedicated-sales model should gain share while weaker channel structures lag.
• If ZBH rallies hard into the next quarter on tariff optics alone, trim exposure and wait for Q2/Q3 evidence; the transitory gross-margin benefit makes near-term results noisier than the medium-term setup.
• For event-driven accounts, buy ZBH on any post-earnings weakness tied to guidance conservatism, but only if the next management commentary confirms no slippage in transitioned territories and no deterioration in pricing beyond the current ~100bp ceiling.